Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?

Panel Discussion and Interactive Q&A

Date

20 Oct 2023

Session

Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

All Speakers

Authors

S. Siena1, K. Ng2, R.A. Adams3, A. Speakers4

Author affiliations

  • 1 Hemato-oncology Dept., UNIMI - Università degli Studi di Milano Statale, 20121 - Milan/IT
  • 2 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 3 Department Of Oncology, Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, CF14 2TL - Cardiff/GB
  • 4 ESMO - European Society for Medical Oncology, GX11 1AA - Lugano/CH

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.